CLINICAL TRIALS PROFILE FOR CIALIS
✉ Email this page to a colleague
All Clinical Trials for cialis
Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
---|---|---|---|---|---|---|
NCT00050609 ↗ | Study of Tadalafil for the Treatment of Diabetic Patients With Symptoms of Upset Stomach and Delayed Stomach Emptying | Completed | ICOS Corporation | Phase 2 | 2003-02-01 | The purposes of this study are to determine whether an experimental drug known as tadalafil can reduce symptoms of dyspepsia (fullness after eating, inability to finish a regular meal, bloating, discomfort or pain in the upper abdomen, belching after meals, nausea, vomiting) in diabetic patients, and/or reduce the amount of time the stomach takes to empty the contents of a standard meal. The safety of tadalafil given once daily for 8 weeks in this population will also be studied. |
NCT00050609 ↗ | Study of Tadalafil for the Treatment of Diabetic Patients With Symptoms of Upset Stomach and Delayed Stomach Emptying | Completed | Eli Lilly and Company | Phase 2 | 2003-02-01 | The purposes of this study are to determine whether an experimental drug known as tadalafil can reduce symptoms of dyspepsia (fullness after eating, inability to finish a regular meal, bloating, discomfort or pain in the upper abdomen, belching after meals, nausea, vomiting) in diabetic patients, and/or reduce the amount of time the stomach takes to empty the contents of a standard meal. The safety of tadalafil given once daily for 8 weeks in this population will also be studied. |
NCT00125918 ↗ | PHIRST-1: Tadalafil in the Treatment of Pulmonary Arterial Hypertension | Completed | ICOS Corporation | Phase 3 | 2005-08-01 | The purpose of this study is to evaluate the safety and effectiveness of tadalafil for the treatment of pulmonary arterial hypertension. |
NCT00125918 ↗ | PHIRST-1: Tadalafil in the Treatment of Pulmonary Arterial Hypertension | Completed | Eli Lilly and Company | Phase 3 | 2005-08-01 | The purpose of this study is to evaluate the safety and effectiveness of tadalafil for the treatment of pulmonary arterial hypertension. |
NCT00174486 ↗ | Assessment Of Duration Of Action, Safety & Toleration Of UK369,003 and Cialis In Patients With Erectile Dysfunction | Completed | Pfizer | Phase 2 | 2005-02-01 | Assessment of duration of action, safety & toleration of different formulations and doses of UK-369,003 and Cialis in patients with male erectile dysfunction. Patients should have previously been on PDE5 inhibitors and have been respondents to the drug. Duration of treatment is 4 weeks. |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for cialis
Condition Name
Clinical Trial Locations for cialis
Trials by Country
Clinical Trial Progress for cialis
Clinical Trial Phase
Clinical Trial Sponsors for cialis
Sponsor Name